Viral transformation for production of personalized type I interferons

被引：1
作者：
Xu, Dongsheng [2 ]
Zhang, Luwen [1 ,2 ]
机构：
[1] Univ Nebraska, Morrison Ctr 238, Nebraska Ctr Virol, Lincoln, NE 68583 USA
[2] Univ Nebraska, Sch Biol Sci, Lincoln, NE 68583 USA
来源：
BIOTECHNOLOGY JOURNAL | 2010年 / 5卷 / 06期
基金：
美国国家卫生研究院;
关键词：
Cytokine; Interferon; Personalized medicine; Red biotechnology; Type I IFNs; EPSTEIN-BARR-VIRUS; INDUCTION; ANTIBODIES; MELANOMA; CELLS;
D O I：
10.1002/biot.201000038
中图分类号：
Q5 [生物化学];
学科分类号：
071010 ; 081704 ;
摘要：
Type I interferons (IFN) are cytokines with many functions and have been widely used to treat many human diseases such as hepatitis C virus infection. Using the viral transformation and priming properties of Epstein-Barr virus, we have developed a system that can produce high levels of "personalized" IFNs, which are produced from the cells of the patient to whom the IFNs are to be administrated. We demonstrate the feasibility of the system. This seems to be the first report for the establishment of a personalized IFN-production system. The personalized IFNs could have a longer circulation time, fewer side effects but higher efficacy. We anticipate that the system can provide an improved form of IFN for medical uses.
引用
收藏
页码：578 / 581
页数：4
相关论文
共 24 条
[1]   Nomenclature of the human interferon proteins [J].
Allen, G ;
Diaz, MO .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (02) :181-182
[2]   Antibodies to interferon (IFN) in hepatitis C patients relapsing while continuing recombinant IFN-alpha 2 therapy [J].
Antonelli, G ;
Giannelli, G ;
Currenti, M ;
Simeoni, E ;
delVecchio, S ;
Maggi, F ;
Pistello, M ;
Roffi, L ;
Pastore, G ;
Chemello, L ;
Dianzani, F .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 104 (03) :384-387
[3]  
Balint Erzsebet, 2004, Acta Microbiologica et Immunologica Hungarica, V51, P359, DOI 10.1556/AMicr.51.2004.3.13
[4]   Impaired antiviral response and alpha/beta interferon induction in mice lacking beta interferon [J].
Deonarain, R ;
Alcamí, A ;
Alexiou, M ;
Dallman, MJ ;
Gewert, DR ;
Porter, ACG .
JOURNAL OF VIROLOGY, 2000, 74 (07) :3404-3409
[5]   Adoptive immunotherapy for EBV-associated malignancies [J].
Gottschalk, S ;
Heslop, HE ;
Rooney, CM .
LEUKEMIA & LYMPHOMA, 2005, 46 (01) :1-10
[6]   IRF-7 is the master regulator of type-I interferon-dependent immune responses [J].
Honda, K ;
Yanai, H ;
Negishi, H ;
Asagiri, M ;
Sato, M ;
Mizutani, T ;
Shimada, N ;
Ohba, Y ;
Takaoka, A ;
Yoshida, N ;
Taniguchi, T .
NATURE, 2005, 434 (7034) :772-777
[7]   Identification of interferon-alpha 7, -alpha 14, and -alpha 21 variants in the genome of a large human population [J].
Hussain, M ;
Gill, DS ;
Liao, MJ .
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1996, 16 (10) :853-859
[8]  
Kieff E., 1996, FIELDS VIROLOGY, P2343
[9]   EPSTEIN-BARR VIRUS-RNA .5. VIRAL-RNA IN A RESTRINGENTLY INFECTED, GROWTH-TRANSFORMED CELL-LINE [J].
KING, W ;
THOMASPOWELL, AL ;
RAABTRAUB, N ;
HAWKE, M ;
KIEFF, E .
JOURNAL OF VIROLOGY, 1980, 36 (02) :506-518
[10]   HUMAN-IGG AND IGM MONOCLONAL-ANTIBODIES AGAINST AUTOLOGOUS MELANOMA PRODUCED BY EPSTEIN-BARR-VIRUS TRANSFORMED LYMPHOCYTES-B [J].
KIRKWOOD, JM ;
ROBINSON, JE .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 1990, 32 (04) :228-234
123